Bosnia and HerzegovinaTuberculosis profile
Population  2016 3.5 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.14 (0.12–0.15) 3.9 (3.4–4.4)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.01 (0.01–0.02)
Incidence  (includes HIV+TB) 1.1 (0.87–1.4) 32 (25–41)
Incidence (HIV+TB only) <0.01 (<0.01–<0.01) 0.06 (0.04–0.09)
Incidence (MDR/RR-TB)** 0 (0–0) 0 (0–0)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.043 (0.032–0.054) 0.34 (0.25–0.42) 0.38 (0.28–0.47)
Males 0.046 (0.034–0.057) 0.71 (0.53–0.88) 0.75 (0.57–0.94)
Total 0.089 (0.067–0.11) 1 (0.78–1.3) 1.1 (0.87–1.4)
TB case notifications, 2016  
Total cases notified 907
Total new and relapse 907
          - % tested with rapid diagnostics at time of diagnosis 0%
          - % with known HIV status <1%
          - % pulmonary 87%
          - % bacteriologically confirmed among pulmonary 75%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 80% (63–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.12 (0.09–0.16)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 1 100%
          - on antiretroviral therapy 1 100%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  0
(0–0)
Estimated % of TB cases with MDR/RR-TB 0% (0–0.67) 0% (0–6.8)  
% notified tested for rifampicin resistance 77% 65% 693
MDR/RR-TB cases tested for resistance to second-line drugs    
Laboratory-confirmed cases MDR/RR-TB: 0, XDR-TB:
Patients started on treatment **** MDR/RR-TB: 0, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 65% 1 092
Previously treated cases, excluding relapse, registered in 2015 0% 3
HIV-positive TB cases registered in 2015   0
MDR/RR-TB cases started on second-line treatment in 2014 67% 3
XDR-TB cases started on second-line treatment in 2014   0
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment 100%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
66% (49–100)
TB financing, 2017  
National TB budget (US$ millions) 12
Funding source: 100% domestic, 0% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2018-05-24 Data: www.who.int/tb/data